The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
Open accessAbstract
Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CL(pro), has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection. Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications). This perspective focuses on the status of various efficacious anti-SARS-CoV 3CL(pro) chemotherapies discovered during the last 12 years (2003-2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening. We describe here mainly peptidomimetic and small molecule inhibitors of SARS-CoV 3CL(pro). Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,026
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406
Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbalenya, A. E. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00865-9 · Cited by 1,198
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., Laman, J. D., de Jong, T., van Doornum, G., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,020
Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835675100 · Cited by 990
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection
Leung, W. K., To, K.-F., Chan, P. K. S., Chan, H. L. Y., Wu, A. K. L., Lee, N., Yuen, K. Y., & Sung, J. J. Y. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01215-0 · Cited by 639
Barretto, N., Jukneliene, D., Ratia, K., Chen, Z., Mesecar, A. D., & Baker, S. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15189-15198.2005 · Cited by 582
Wen, C.-C., Kuo, Y.-H., Jan, J.-T., Liang, P.-H., Wang, S.-Y., Liu, H.-G., Lee, C.-K., Chang, S.-T., Kuo, C.-J., Lee, S.-S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070295s · Cited by 576
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition
Ryu, Y. B., Jeong, H. J., Kim, J. H., Kim, Y. M., Park, J.-Y., Kim, D., Naguyen, T. T. H., Park, S.-J., Chang, J. S., Park, K. H., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.035 · Cited by 546
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, H., Zhu, L., Jiang, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11334-11339.2004 · Cited by 485
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J.-P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 477
Ratia, K., Saikatendu, K. S., Santarsiero, B. D., Barretto, N., Baker, S. C., Stevens, R. C., & Mesecar, A. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510851103 · Cited by 414
Lee, H.-J., Shieh, C.-K., Gorbalenya, A. E., Koonin, E. V., La Monica, N., Tuler, J., Bagdzhadzhyan, A., & Lai, M. M. C. (1991) · Virology · doi:10.1016/0042-6822(91)90071-i · Cited by 369
A MURINE VIRUS (JHM) CAUSING DISSEMINATED ENCEPHALOMYELITIS WITH EXTENSIVE DESTRUCTION OF MYELIN
Cheever, F. S., Daniels, J. B., Pappenheimer, A. M., & Bailey, O. T. (1949) · Journal of Experimental Medicine · doi:10.1084/jem.90.3.181 · Cited by 354
Dougherty, W. G., & Semler, B. L. (1993) · Microbiological Reviews · doi:10.1128/mmbr.57.4.781-822.1993 · Cited by 345
Fluoro ketone inhibitors of hydrolytic enzymes
Gelb, M. H., Svaren, J. P., & Abeles, R. H. (1985) · Biochemistry · doi:10.1021/bi00329a001 · Cited by 343
Fan, K., Wei, P., Feng, Q., Chen, S., Huang, C., Ma, L., Lai, B., Pei, J., Liu, Y., Chen, J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310875200 · Cited by 327
Conservation of substrate specificities among coronavirus main proteases
Hegyi, A., & Ziebuhr, J. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-3-595 · Cited by 322
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Doerr, H. W., Hunsmann, G., Otaka, A., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.083 · Cited by 306
The Crystal Structure of Cruzain: A Therapeutic Target for Chagas' Disease
McGrath, M. E., Eakin, A. E., Engel, J. C., McKerrow, J. H., Craik, C. S., & Fletterick, R. J. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.0137 · Cited by 269
Coronaviruses: A Comparative Review
McIntosh, K. (1974) · Current Topics in Microbiology and Immunology / Ergebnisse der Mikrobiologie und Immunitätsforschung · doi:10.1007/978-3-642-65775-7_3 · Cited by 266
Chen, L., Li, J., Luo, C., Liu, H., Xu, W., Chen, G., Liew, O. W., Zhu, W., Puah, C. M., Shen, X., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.014 · Cited by 265
Mechanism of the Maturation Process of SARS-CoV 3CL Protease
Hsu, M.-F., Kuo, C.-J., Chang, K.-T., Chang, H.-C., Chou, C.-C., Ko, T.-P., Shr, H.-L., Chang, G.-G., Wang, A. H.-J., & Liang, P.-H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502577200 · Cited by 262
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Tan, E. L. C., Ooi, E. E., Lin, C.-Y., Tan, H. C., Ling, A. E., Lim, B., & Stanton, L. W. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1004.030458 · Cited by 237
A MURINE VIRUS (JHM) CAUSING DISSEMINATED ENCEPHALOMYELITIS WITH EXTENSIVE DESTRUCTION OF MYELIN
Bailey, O. T., Pappenheimer, A. M., Cheever, F. S., & Daniels, J. B. (1949) · Journal of Experimental Medicine · doi:10.1084/jem.90.3.195 · Cited by 228
Preparation of trifluoromethyl ketones and related fluorinated ketones
Bégué, J.-P., & Bonnet-Delpon, D. (1991) · Tetrahedron · doi:10.1016/s0040-4020(01)86391-2 · Cited by 225
Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic Correlates
Tsui, P. T., Kwok, M. L., Yuen, H., & Lai, S. T. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0909.030362 · Cited by 220
Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLpro
Bacha, U., Barrila, J., Velazquez-Campoy, A., Leavitt, S. A., & Freire, E. (2004) · Biochemistry · doi:10.1021/bi0361766 · Cited by 218
3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism
Huang, C., Wei, P., Fan, K., Liu, Y., & Lai, L. (2004) · Biochemistry · doi:10.1021/bi036022q · Cited by 215
Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α
Ströher, U., DiCaro, A., Li, Y., Strong, J. E., Aoki, F., Plummer, F., Jones, S. M., & Feldmann, H. (2004) · The Journal of Infectious Diseases · doi:10.1086/382597 · Cited by 210
Virtual Screening and Its Integration with Modern Drug Design Technologies
Andricopulo, A., Guido, R., & Oliva, G. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783330683 · Cited by 209
Treatment of Wilson’s disease with zinc. XVII: Treatment during pregnancy
Brewer, G. J., Johnson, V. D., Dick, R. D., Hedera, P., Fink, J. K., & Kluin, K. J. (2000) · Hepatology · doi:10.1002/hep.510310216 · Cited by 208
High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase
Blanchard, J. E., Elowe, N. H., Huitema, C., Fortin, P. D., Cechetto, J. D., Eltis, L. D., & Brown, E. D. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.011 · Cited by 206
Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301580n · Cited by 200
Grum-Tokars, V., Ratia, K., Begaye, A., Baker, S. C., & Mesecar, A. D. (2008) · Virus Research · doi:10.1016/j.virusres.2007.02.015 · Cited by 190
Shi, J., Wei, Z., & Song, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311744200 · Cited by 190
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii
Ryu, Y. B., Park, S.-J., Kim, Y. M., Lee, J.-Y., Seo, W. D., Chang, J. S., Park, K. H., Rho, M.-C., & Lee, W. S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.152 · Cited by 190
Recent Development and Application of Virtual Screening in Drug Discovery: An Overview
Hou, T., & Xu, X. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452721 · Cited by 189
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors
Chen, L.-R., Wang, Y.-C., Lin, Y. W., Chou, S.-Y., Chen, S.-F., Liu, L. T., Wu, Y.-T., Kuo, C.-J., Chen, T. S.-S., & Juang, S.-H. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.027 · Cited by 180
Lee, T.-W., Cherney, M. M., Huitema, C., Liu, J., James, K. E., Powers, J. C., Eltis, L. D., & James, M. N. G. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.004 · Cited by 170
Lu, I.-L., Mahindroo, N., Liang, P.-H., Peng, Y.-H., Kuo, C.-J., Tsai, K.-C., Hsieh, H.-P., Chao, Y.-S., & Wu, S.-Y. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060207o · Cited by 161
Yang, S., Chen, S.-J., Hsu, M.-F., Wu, J.-D., Tseng, C.-T. K., Liu, Y.-F., Chen, H.-C., Kuo, C.-W., Wu, C.-S., Chang, L.-W., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603926 · Cited by 161
Design, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease
Webber, S. E., Tikhe, J. G., Worland, S. T., Fuhrman, S. A., Hendrickson, T. F., Matthews, D. A., Love, R. A., Patick, A. K., Meador, J. W., Ferre, R. A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960603e · Cited by 159
Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate
Kuo, C.-J., Chi, Y.-H., Hsu, J. T.-A., & Liang, P.-H. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.098 · Cited by 158
A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease
Tong, L., Qian, C., Massariol, M.-J., Bonneau, P. R., Cordingley, M. G., & Lagacé, L. (1996) · Nature · doi:10.1038/383272a0 · Cited by 157
Kao, R. Y., Tsui, W. H. W., Lee, T. S. W., Tanner, J. A., Watt, R. M., Huang, J.-D., Hu, L., Chen, G., Chen, Z., Zhang, L., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.07.013 · Cited by 156
Zhang, Z., Poorman, R. A., Maggiora, L. L., Heinrikson, R. L., & Kézdy, F. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98445-0 · Cited by 150
Design of potent selective zinc-mediated serine protease inhibitors
Katz, B. A., Clark, J. M., Finer-Moore, J. S., Jenkins, T. E., Johnson, C. R., Ross, M. J., Luong, C., Moore, W. R., & Stroud, R. M. (1998) · Nature · doi:10.1038/35422 · Cited by 150
Ghosh, A. K., Xi, K., Ratia, K. M., Santarsiero, B. D., Fu, W., Harcourt, B. H., Rota, P. A., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050548m · Cited by 142
Ghosh, A. K., Gong, G., Grum-Tokars, V. L., Mulhearn, D. C., Baker, S. C., Coughlin, M. M., Prabhakar, B. S., Sleeman, K., Johnson, M. E., & Mesecar, A. D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.082 · Cited by 137
Wu, C., King, K., Kuo, C., Fang, J., Wu, Y., Ho, M., Liao, C.-L., Shie, J., Liang, P., & Wong, C. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.12.008 · Cited by 131
Zhu, L., George, S., Schmidt, M. F., Al‐Gharabli, S., Rademann, J., & Hilgenfeld, R. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.08.001 · Cited by 125
Turlington, M., Chun, A. C., Tomar, S., Eggler, A. L., Grum-Tokars, V. L., Jacobs, J., Daniels, J. S., Dawson, E. S., Saldanha, A., Chase, P. S., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.112 · Cited by 125
Ribavirin in the treatment of SARS: A new trick for an old drug?
Koren, G., King, S., Knowles, S. R., & Phillips, E. W. (2003) · Europe PMC (PubMed Central) · Cited by 124
Wu, C., Chang, C., Chen, J. S., Wong, C., & Lin, C. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200351823 · Cited by 121
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors
Ramajayam, R., Tan, K.-P., Liu, H.-G., & Liang, P. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.050 · Cited by 120
Development of New Drugs for an Old Target — The Penicillin Binding Proteins
Zervosen, A., Sauvage, E., Frère, J., Charlier, P., & Luxen, A. (2012) · Molecules · doi:10.3390/molecules171112478 · Cited by 117
Shie, J., Fang, J., Kuo, T., Kuo, C., Liang, P., Huang, H., Wu, Y.-T., Jan, J., Cheng, Y. E., & Wong, C. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.05.065 · Cited by 111
Inhibiting the assembly of protein—protein interfaces
Zutshi, R., Brickner, M., & Chmielewski, J. A. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80036-7 · Cited by 110
Chen, D., Chen, L., Tan, J., Chen, J., Du, L., Sun, T., Shen, J., Chen, K., Jiang, H., & Shen, X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408211200 · Cited by 106
Pillaiyar, T., Konno, S., Yamamoto, T., Koiwai, Y., Taguchi, A., Takayama, K., Yakushiji, F., Akaji, K., Chen, S.-E., Naser‐Tavakolian, A., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.037 · Cited by 106
Self-citationWeber, I. T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86974-5 · Cited by 104
Ghosh, A. K., Xi, K., Grum-Tokars, V. L., Xu, X., Ratia, K. M., Fu, W., Houser, K. V., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.031 · Cited by 102
Jain, R. P., Pettersson, H. I., Zhang, J., Aull, K. H., Fortin, P. D., Huitema, C., Eltis, L. D., Parrish, J. C., James, M. N. G., Wishart, D. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0494873 · Cited by 102
Discovery of Potent Anilide Inhibitors against the Severe Acute Respiratory Syndrome 3CL Protease
Shie, J., Fang, J., Kuo, C., Kuo, T., Liang, P., Huang, H., Yang, W., Lin, C., Chen, J.-L., Wu, Y.-T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050184y · Cited by 102
The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase
Wei, P., Fan, K., Chen, H., Ma, L., Huang, C., Tan, L., Xi, D., Li, C., Liu, Y., Cao, A., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.102 · Cited by 101
Structure-Based Design, Synthesis, and Evaluation of Peptide-Mimetic SARS 3CL Protease Inhibitors
Akaji, K., Konno, H., Mitsui, H., Teruya, K., Shimamoto, Y., Hattori, Y., Ozaki, T., Kusunoki, M., & Sanjoh, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200870n · Cited by 100
Liu, W., Zhu, H.-M., Niu, G.-J., Shi, E.-Z., Chen, J., Sun, B., Chen, W., Zhou, H., & Yang, C. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.028 · Cited by 98
Medeiros, R., Kitazawa, M., Chabrier, M. A., Cheng, D., Baglietto‐Vargas, D., Kling, A., Möller, A., Green, K. N., & LaFerla, F. M. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.020 · Cited by 96
Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV
Hsu, J. T.-A., Kuo, C., Hsieh, H., Wang, Y.-C., Huang, K., Lin, C. P. C., Huang, P.-F., Chen, X., & Liang, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.08.015 · Cited by 94
MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity
Wu, Y., Guastella, J., Huang, J., Wang, Y., Zhang, L., Xue, D., Tran, M. B., Woodward, R. M., Kasibhatla, S., Tseng, B., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705450 · Cited by 92
Zhang, H., Zhang, H., Kemnitzer, W. E., Tseng, B., Cinatl, J. J., Michaelis, M., Doerr, H. W., & Cai, S. X. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0507678 · Cited by 90
Zhang, J., Pettersson, H. I., Huitema, C., Niu, C., Yin, J., James, M. N. G., Eltis, L. D., & Vederas, J. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061425k · Cited by 89
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
Shao, Y.-M., Yang, W., Kuo, T., Tsai, K., Lin, C., Yang, A., Liang, P., & Wong, C. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.040 · Cited by 88
Bond, C. W., Leibowitz, J. L., & Robb, J. A. (1979) · Virology · doi:10.1016/0042-6822(79)90468-9 · Cited by 86
Verschueren, K. H. G., Pumpor, K., Anemüller, S., Chen, S., Mesters, J. R., & Hilgenfeld, R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.04.011 · Cited by 86
Konno, S., Pillaiyar, T., Yamamoto, T., Nakada, K., Kakiuchi, R., Takayama, K., Yamazaki, Y., Yakushiji, F., Akaji, K., Kiso, Y., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.017 · Cited by 84
Self-citationFused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors
Shimamoto, Y., Hattori, Y., Kobayashi, K., Teruya, K., Sanjoh, A., Nakagawa, A., Yamashita, E., & Akaji, K. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.028 · Cited by 81
The inhibition of human immunodeficiency virus proteases by ‘interface peptides’
Schramm, H. J., Boetzel, J., Büttner, J., Fritsche, E., Göhring, W., Jaeger, E., KONIG, S., Thumfart, J. O., Wenger, T., & NAGEL, N. (1996) · Antiviral Research · doi:10.1016/0166-3542(96)00940-0 · Cited by 79
The pharmacology of the insulinomimetic effect of zinc complexes
Sakurai, H., & Adachi, Y. (2005) · BioMetals · doi:10.1007/s10534-005-3688-8 · Cited by 76
Biological Properties of Avian Coronavirus RNA
Lomniczi, B. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-3-531 · Cited by 76
Discovery of a Novel Family of SARS-CoV Protease Inhibitors by Virtual Screening and 3D-QSAR Studies
Tsai, K., Chen, S., Liang, P., Lu, I.-L., Mahindroo, N., Hsieh, H., Chao, Y., Liu, L., Liu, D., Lien, W., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050852f · Cited by 75
Aza-Peptide Epoxides: A New Class of Inhibitors Selective for Clan CD Cysteine Proteases
Asgian, J. L., James, K. E., Li, Z. Z., Carter, W., Barrett, A. J., Mikolajczyk, J., Salvesen, G. S., & Powers, J. C. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025581c · Cited by 72
Pillaiyar, T., Konno, S., Yamamoto, T., Koiwai, Y., Taguchi, A., Takayama, K., Yakushiji, F., Akaji, K., Kiso, Y., Kawasaki, Y., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.05.005 · Cited by 69
Self-citationAdvances in the development of thrombin inhibitors
Steinmetzer, T., Hauptmann, J., & Stürzebecher, J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.5.845 · Cited by 67
Structural basis of mercury‐ and zinc‐conjugated complexes as SARS‐CoV 3C‐like protease inhibitors
Lee, C., Kuo, C., Hsu, M., Liang, P., Fang, J., Shie, J., & Wang, A. H. ‐. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.10.048 · Cited by 66
HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease
Schramm, H. J., Nakashima, H., Schramm, W., Wakayama, H., & Yamamoto, N. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91895-j · Cited by 64
Lee, H., Mittal, A., Patel, K., Gatuz, J. L., Truong, L., Torres, J., Mulhearn, D. C., & Johnson, M. E. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.041 · Cited by 62
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
Ramajayam, R., Tan, K.-P., Liu, H., & Liang, P. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.118 · Cited by 60
Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy
Ghosh, A. K., Xi, K., Johnson, M. E., Baker, S. C., & Mesecar, A. D. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41011-3 · Cited by 58
Lee, T.-W., Cherney, M. M., Liu, J., James, K. E., Powers, J. C., Eltis, L. D., & James, M. N. G. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.078 · Cited by 58
Kaeppler, U., Stiefl, N., Schiller, M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501782 · Cited by 58
Regnier, T., Sarma, D., Hidaka, K., Bacha, U., Freire, E., Hayashi, Y., & Kiso, Y. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.118 · Cited by 55
Self-citationOral zinc sulfate in the treatment of Behcet's disease: A double blind cross‐over study
Sharquie, K. E., Najim, R. A., Dori, W. S. A., & Hayani, R. K. (2006) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2006.00128.x · Cited by 53
Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits
Mukherjee, P. K., Desai, P. V., Ross, L. J., White, E. L., & Avery, M. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.01.011 · Cited by 52
Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
Liu, Y.-C., Huang, V., Chao, T., Hsiao, C., Lin, A., Chang, M., & Chow, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.095 · Cited by 48
VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis
Weber, P., Wang, P., Maddens, S., Wang, P. S., Wu, R., Miksa, M., Dong, W., Mortimore, M., Golec, J. M. C., & Charlton, P. (2009) · Critical Care · doi:10.1186/cc8041 · Cited by 48
Dimerization Inhibitors of HIV-1 Protease
Boggetto, N., & Reboud‐Ravaux, M. (2002) · Biological Chemistry · doi:10.1515/bc.2002.150 · Cited by 45
Nguyen, T. T. H., Ryu, H.-J., Lee, S., Hwang, S., Breton, V., Rhee, J. H., & Kim, D. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.034 · Cited by 43
Zhang, J., Huitema, C., Niu, C., et al. (2008) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2008.01.001 · Cited by 41
Martina, E., Stiefl, N., Degel, B., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.012 · Cited by 41
Targeting the dimerization interface for irreversible inhibition of HIV-1 protease
Zutshi, R., & Chmielewski, J. A. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00369-3 · Cited by 39
Niu, C., Yin, J., Zhang, J., Vederas, J. C., & James, M. N. G. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.09.034 · Cited by 39
Richer, J. K., Hunt, W. G., Sakanari, J. A., & Grieve, R. B. (1993) · Experimental Parasitology · doi:10.1006/expr.1993.1027 · Cited by 38
Apixaban: A novel oral inhibitor of factor Xa
Nutescu, E. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110418 · Cited by 38
Structure‐Based Design and Synthesis of Highly Potent SARS‐CoV 3CL Protease Inhibitors
Shao, Y., Yang, W., Peng, H., Hsu, M., Tsai, K., Kuo, T., Wang, A. H. ‐., Liang, P., Lin, C., Yang, A., et al. (2007) · ChemBioChem · doi:10.1002/cbic.200700254 · Cited by 34
Current status of severe acute respiratory syndrome in China
Nie, Q. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i8.1635 · Cited by 31
Ikejiri, M., Saijo, M., Morikawa, S., Fukushi, S., Mizutani, T., Kurane, I., & Maruyama, T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.026 · Cited by 30
Pillaiyar, T. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000287 · Cited by 27
Self-citationWHO investigates China's fall in SARS cases
Parry, J. (2003) · BMJ · doi:10.1136/bmj.326.7402.1285-c · Cited by 16
WHO says SARS outbreak is over, but fight should go on
Fleck, F. (2003) · BMJ · doi:10.1136/bmj.327.7406.70-c · Cited by 12
WHO declares Beijing to be free of SARS
Ashraf, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13790-7 · Cited by 11
Cited by
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
Tahir ul Qamar, M., Alqahtani, S. M., Alamri, M. A., & Chen, L.-L. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.009 · Cited by 1,032
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
Metadata
- Authors
- Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-02-15
- Volume
- 59
- Issue
- 14
- Pages
- 6595-6628
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2284201926
- Cited by
- 775
- References
- 123
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.